secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-037936
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax Q2 net loss $44.6M; axatilimab ORR up to 74% in cGVHD; two filings on track for 2023
--------------------------------------------------------------------------------

- Axatilimab AGAVE-201: ORR 74% at 0.3 mg/kg Q2W; all three cohorts met primary endpoint in cGVHD.
- Revumenib AUGMENT-101 topline data from KMT2Ar cohorts expected Q3 2023; NDA filing by year-end.
- Q2 2023 net loss $44.6M ($0.64/sh) vs $37.6M ($0.62/sh) in Q2 2022.
- Cash and investments $418.3M; 69.7M shares outstanding.
- FY 2023 R&D guidance $160-175M; total operating expenses $225-240M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023037936/0000950170-23-037936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023037936/sndx-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer